When the effect goes further than intended
These medications work by reducing how much you want to eat. The Wegovy® and Zepbound® labels both describe GLP-1 as a physiological regulator of appetite and caloric intake, and the trials that support them included a reduced calorie diet as part of treatment. So eating less is expected. The problem this guide is about is the point past that, where intake falls low enough to cause dehydration, low blood sugar, weakness or, over months, the loss of muscle and nutrients. It sets out what the labels warn, what two 2026 reviews found through PubMed report, the practical points those sources support, and when to tell your provider.
This is general information and not medical advice. The labels and reviews describe the FDA-approved products; personalized compounded semaglutide and tirzepatide, which Bodi Envi’s programs may include, are not FDA-approved and were not studied in the cited trials. What and how much you should eat is a question for your licensed provider, and this guide gives no diet plan.
Personalized compounded medications differ from commercially available brand-name products in formulation, concentration, excipients, preparation methods, and other characteristics. Accordingly, clinical data from studies involving brand-name products should not be assumed to apply to personalized compounded formulations.
At this time, the studies referenced above have not evaluated the specific personalized compounded formulations being provided. Therefore, no claims of equivalence in safety, efficacy, quality, or clinical outcomes should be inferred from these studies.
What the labels warn about
The labels do not have a section on under eating as such. What they have is a set of warnings whose common thread is reduced intake of food and fluid.
Acute kidney injury due to volume depletion. Both labels report postmarketing cases of acute kidney injury, in some cases requiring dialysis, and state that the majority occurred in patients who experienced gastrointestinal reactions leading to dehydration, such as nausea, vomiting or diarrhea. Both advise monitoring kidney function in patients reporting reactions that could lead to volume depletion, especially during initiation and escalation. Both medication guides tell patients that diarrhea, nausea and vomiting may cause a loss of fluids that can cause kidney problems and that it is important to drink fluids to reduce that chance.
Hypoglycemia. Both labels warn that the medication lowers blood glucose and can cause low blood sugar, with the risk increased in combination with insulin or a sulfonylurea. The Zepbound® label reports hypoglycemia in 4.2 percent of treated patients with type 2 diabetes against 1.3 percent on placebo. The labels list the signs: dizziness or light-headedness, sweating, shakiness, blurred vision, slurred speech, weakness, anxiety, hunger, headache, irritability, confusion, fast heartbeat. Several of those signs overlap with simply not having eaten.
The common reactions. Both labels list dizziness and fatigue among reactions reported more often than placebo, and the Zepbound® label lists hypotension, low blood pressure, in 1 to 2 percent of treated patients against none on placebo. Reduced intake of food and fluid is one plausible contributor to all three.
Gallbladder disease. The Wegovy® label’s counselling section says that substantial or rapid weight loss can increase the risk of gallbladder disease, and asks patients to contact their provider if it is suspected. This is the one place a label ties a risk to the pace of weight loss itself.
Personalized compounded medications differ from commercially available brand-name products in formulation, concentration, excipients, preparation methods, and other characteristics. Accordingly, clinical data from studies involving brand-name products should not be assumed to apply to personalized compounded formulations.
At this time, the studies referenced above have not evaluated the specific personalized compounded formulations being provided. Therefore, no claims of equivalence in safety, efficacy, quality, or clinical outcomes should be inferred from these studies.
What the reviews report
Two peer reviewed reviews from 2026, found through PubMed, take the question further than the labels do.
A narrative review by Fujioka in Nutrition in Clinical Practice examines how these medications change appetite and intake. According to its abstract, they significantly reduce meal size and may decrease overall water intake, the choice of highly palatable foods is affected, most patients will experience gastrointestinal side effects that can often be managed with dietary adjustments, loss of lean tissue including bone and muscle has been reported, and vitamin deficiencies have been reported now that the medications have been available for several years. The author’s conclusion is that clinicians’ nutritional counselling becomes invaluable given the intended appetite suppression.
A review by Nobakht and colleagues in Cardiorenal Medicine focuses on muscle. According to its abstract, weight loss on incretin-based therapies is typically fat-predominant, but available studies suggest approximately 25 to 39 percent of total weight loss may reflect a reduction in lean body mass over 36 to 72 weeks. The authors note that muscle mass, strength and function are inconsistently measured in trials, and they propose a stepwise approach that pairs prescribing with baseline muscle risk assessment, tracking of body composition and simple functional measures, and early mitigation through resistance training and nutrition optimization.
Neither review gives a number for how little is too little, and this guide does not either. What they establish is that reduced intake is expected, that it has consequences beyond weight when it goes too far, and that those consequences are something a provider can watch for and address.
Personalized compounded medications differ from commercially available brand-name products in formulation, concentration, excipients, preparation methods, and other characteristics. Accordingly, clinical data from studies involving brand-name products should not be assumed to apply to personalized compounded formulations.
At this time, the studies referenced above have not evaluated the specific personalized compounded formulations being provided. Therefore, no claims of equivalence in safety, efficacy, quality, or clinical outcomes should be inferred from these studies.
What the sources support doing
The practical list here is limited to what the labels and the two reviews support.
Drink fluids. This is the labels’ own instruction, tied to their kidney injury warning, and the Fujioka review adds that water intake may fall along with food. Fluids do not depend on appetite.
Eat regularly, even in small amounts. The reviews describe reduced meal size as the mechanism, and the labels’ hypoglycemia and dizziness warnings describe what happens when intake falls too far. Smaller, regular meals follow from both; what those meals should contain is a question for your provider, and the guide on this site to eating well on treatment reports only what the Dietary Guidelines for Americans and the labels support.
Move, including resistance work. The Nobakht review names resistance training as a mitigation for lean mass loss, and both labels say the medication is to be used with increased physical activity. What activity is appropriate for you is, again, your provider’s call.
Raise nutrition with your provider. Both reviews conclude that nutritional counselling matters for people on these medications, and the Fujioka review reports vitamin deficiencies. Whether you need any assessment or supplement is a clinical question, not one a guide can answer.
Do not adjust the dose yourself. The labels give a provider the tools to respond to a dose that is doing more than intended: delaying an increase by four weeks under the Wegovy® label, choosing a lower maintenance dose under the Zepbound® label. With a compounded prescription, your dose is your provider’s decision, and the FDA has warned specifically about patients changing compounded doses on their own.
When to contact your provider or seek care
The labels’ counselling sections set the triggers. Persistent nausea, vomiting or diarrhea should be reported promptly because of the risk of dehydration and kidney injury. The signs of low blood sugar listed above, especially if you take insulin or a sulfonylurea, should be reported. Dizziness, weakness or fainting, or an inability to keep fluids down, are reasons to seek care rather than wait. And the labels’ urgent symptoms apply regardless: severe abdominal pain that does not go away, symptoms of a serious allergic reaction, and the signs of gallbladder disease.
From the reviews, the softer signals are also worth reporting: going most days without eating regularly, noticeable loss of strength, or hair loss, which both labels list among common reactions. None of those is an emergency; all of them are things a provider would want to know.
What the care team messaging is for
Bodi Envi’s programs include ongoing messaging with your care team through the patient portal, and a change in how you are eating is a good reason to use it. Message when intake has fallen to the point of skipping most meals, when you are not managing fluids, when you feel faint or weak, or when you want to ask about nutrition or activity. A licensed provider, through Wasef Health, PC for applicable programs, makes the clinical decisions, including any change to the dose.
Bodi Envi is a telehealth platform and not a medical practice, pharmacy or medication manufacturer. Personalized Compounded semaglutide and tirzepatide are not FDA-approved and are not equivalent to the approved products; the labels and reviews cited describe the branded products. This is general information and not medical advice, and your licensed provider is the person to ask about what and how much to eat.